Table 2. CAR-T cells in multiple myeloma: outcome comparison.

	CARTITUDE-1 (cilta-cel)	KARMMA (ide-cel)
Number of patients	97	128
Median number of prior lines	6	6
ORR/≥CR, %	97.9/80.4	73/33
MRD 10−5 negativity	93 (n = 57)	26
PFS, months	18-month PFS: 66%	Median: 8.6
Median DOR, months	21.8	10.7
CRS, %	95 4% grade 3/4	84 grade ≥3, 5%
ICANS, %	21 grade ≥3, 10%	18 grade ≥3, 0%

CAR-T, chimeric antigen receptor T; CR, complete response; CRS, cytokine release syndrome; DOR, duration of response; ICANS, immune effector cell-associated neurotoxicity syndrome; MRD, minimal residual disease; ORR, overall response rate; PFS, progression-free survival